77 related articles for article (PubMed ID: 25834914)
1. [Recent process of molecular target therapies in ovarian serous and endometrioid carcinomas on basis of intergrated genomic characterization].
Oda K
Gan To Kagaku Ryoho; 2015 Feb; 42(2):169-73. PubMed ID: 25834914
[No Abstract] [Full Text] [Related]
2. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG
Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiles in three histologic types, clear-cell, endometrioid and serous ovarian carcinomas.
Pamuła-Piłat J; Rubel T; Rzepecka IK; Olbryt M; Herok R; Dansonka-Mieszkowska A; Grzybowska E; Kupryjańczyk J
J Biol Regul Homeost Agents; 2014; 28(4):659-74. PubMed ID: 25620176
[TBL] [Abstract][Full Text] [Related]
4. The histomorphology of Lynch syndrome-associated ovarian carcinomas: toward a subtype-specific screening strategy.
Chui MH; Ryan P; Radigan J; Ferguson SE; Pollett A; Aronson M; Semotiuk K; Holter S; Sy K; Kwon JS; Soma A; Singh N; Gallinger S; Shaw P; Arseneau J; Foulkes WD; Gilks CB; Clarke BA
Am J Surg Pathol; 2014 Sep; 38(9):1173-81. PubMed ID: 25025451
[TBL] [Abstract][Full Text] [Related]
5. Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates.
Gurung A; Hung T; Morin J; Gilks CB
Histopathology; 2013 Jan; 62(1):59-70. PubMed ID: 23240670
[TBL] [Abstract][Full Text] [Related]
6. Re: Madore et al. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. J Pathol 2010;220:392-400.
Stewart CJ
J Pathol; 2010 Sep; 222(1):117; author reply 118. PubMed ID: 20572050
[No Abstract] [Full Text] [Related]
7. Epithelial neoplasms of the ovary. An update on current concepts.
Gordon MD; Ireland K
Clin Lab Med; 1995 Sep; 15(3):575-93. PubMed ID: 8542724
[TBL] [Abstract][Full Text] [Related]
8. Frameshift mutations in the bax gene are not involved in development of ovarian endometrioid carcinoma.
Cao SN; Chang KH; Luthra R; Liu J
Mod Pathol; 2003 Oct; 16(10):1048-52. PubMed ID: 14559989
[TBL] [Abstract][Full Text] [Related]
9. Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms.
Bidus MA; Webb JC; Seidman JD; Rose GS; Boice CR; Elkas JC
Gynecol Oncol; 2006 Jul; 102(1):5-7. PubMed ID: 16697451
[TBL] [Abstract][Full Text] [Related]
10. Functional analysis of genes in regions commonly amplified in high-grade serous and endometrioid ovarian cancer.
Davis SJ; Sheppard KE; Pearson RB; Campbell IG; Gorringe KL; Simpson KJ
Clin Cancer Res; 2013 Mar; 19(6):1411-21. PubMed ID: 23362323
[TBL] [Abstract][Full Text] [Related]
11. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses.
Lax SF; Kurman RJ
Verh Dtsch Ges Pathol; 1997; 81():228-32. PubMed ID: 9474874
[TBL] [Abstract][Full Text] [Related]
12. Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas.
McConechy MK; Anglesio MS; Kalloger SE; Yang W; Senz J; Chow C; Heravi-Moussavi A; Morin GB; Mes-Masson AM; ; Carey MS; McAlpine JN; Kwon JS; Prentice LM; Boyd N; Shah SP; Gilks CB; Huntsman DG
J Pathol; 2011 Apr; 223(5):567-73. PubMed ID: 21381030
[TBL] [Abstract][Full Text] [Related]
13. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
14. Pathogenetic pathways in ovarian endometrioid adenocarcinoma: a molecular study of 29 cases.
Geyer JT; López-García MA; Sánchez-Estevez C; Sarrió D; Moreno-Bueno G; Franceschetti I; Palacios J; Oliva E
Am J Surg Pathol; 2009 Aug; 33(8):1157-63. PubMed ID: 19542870
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.
Zorn KK; Bonome T; Gangi L; Chandramouli GV; Awtrey CS; Gardner GJ; Barrett JC; Boyd J; Birrer MJ
Clin Cancer Res; 2005 Sep; 11(18):6422-30. PubMed ID: 16166416
[TBL] [Abstract][Full Text] [Related]
16. [Molecular carcinogenesis of ovarian carcinoma].
Diebold J
Verh Dtsch Ges Pathol; 2005; 89():77-83. PubMed ID: 18035676
[TBL] [Abstract][Full Text] [Related]
17. Loss of cables, a novel gene on chromosome 18q, in ovarian cancer.
Dong Q; Kirley S; Rueda B; Zhao C; Zukerberg L; Oliva E
Mod Pathol; 2003 Sep; 16(9):863-8. PubMed ID: 13679449
[TBL] [Abstract][Full Text] [Related]
18. [Five years survival in patients with endometrioid ovarian cancer versus patients with serous ovarian cancer].
Ivanov S; Batashki I
Akush Ginekol (Sofiia); 2008; 47(5):9-11. PubMed ID: 19227770
[TBL] [Abstract][Full Text] [Related]
19. B7-H4 overexpression in ovarian tumors.
Tringler B; Liu W; Corral L; Torkko KC; Enomoto T; Davidson S; Lucia MS; Heinz DE; Papkoff J; Shroyer KR
Gynecol Oncol; 2006 Jan; 100(1):44-52. PubMed ID: 16256178
[TBL] [Abstract][Full Text] [Related]
20. Human leucocyte antigen (HLA) A2 as a negative clinical prognostic factor in patients with advanced ovarian cancer.
Gamzatova Z; Villabona L; Dahlgren L; Dalianis T; Nillson B; Bergfeldt K; Masucci GV
Gynecol Oncol; 2006 Oct; 103(1):145-50. PubMed ID: 16542716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
